Chembio Diagnostics

Chembio Diagnostics is a leading point-of-care diagnostic company dedicated to the detection and diagnosis of infectious diseases, including COVID-19, sexually transmitted diseases, as well as fever and tropical diseases. Combined with Chembio's extensive scientific expertise, its innovative DPP® technology offers a wide range of market applications beyond infectious diseases. Chembio’s products are sold globally to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers either directly or through distributors. About the DPP Rapid Test Platform: Chembio’s proprietary DPP® technology platform provides high-quality, rapid diagnostic results within 15 to 20 minutes using a small drop of blood from a fingerstick or other samples. Through advanced multiplexing, the DPP platform can detect up to eight different test results from a single patient sample, offering greater clinical value than other rapid tests. For certain applications, Chembio’s easy-to-use, highly portable, battery-powered DPP Micro Reader optical analyzer can report accurate results in approximately 15 seconds, making it ideal for decentralized testing where real-time results enable clinical evaluation of patients while they are still on-site. The objective results generated by the DPP Micro Reader reduce the likelihood of human errors that may occur in the visual interpretation required by many rapid tests. Chembio’s FDA-regulated portfolio of DPP-based point-of-care tests includes the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Test (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, ANVISA (Agência Nacional de Vigilância Sanitária), and other global organizations.